Press release
Analysis of Key Market Segments Driving the Tyrosine Kinase Inhibitors Market
Tyrosine Kinase Inhibitors
Projected Growth and Market Size of the Tyrosine Kinase Inhibitors Industry
The tyrosine kinase inhibitors market is poised for substantial expansion, expected to reach $87.14 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.6%. This upward trajectory is fueled by increased healthcare funding, the rise of biomarker-driven therapies, advancements in drug delivery systems, and the growing focus on precision medicine, particularly in pediatric oncology. Key trends anticipated during this period include strategies to overcome drug resistance, development of central nervous system-penetrant TKIs, expanding non-oncology uses, liquid biopsy technologies for disease monitoring, and considerations related to health economics.
Download a free sample of the tyrosine kinase inhibitors market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11957&type=smp
Leading Corporations Driving the Tyrosine Kinase Inhibitors Market
Several influential players dominate the tyrosine kinase inhibitors market landscape. Major companies include Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd, Incyte Corporation, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Glenmark Pharmaceuticals Ltd, Blueprint Medicines Corporation, Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., and ArQule Inc.
Strategic Acquisition Enhancing Market Presence
In June 2022, Bristol Myers Squibb, a US-based pharmaceutical firm, completed the acquisition of Turning Point Therapeutics Inc. for an undisclosed amount. This move strengthens Bristol Myers Squibb's oncology portfolio and enables full utilization of its precision oncology platform to improve cancer treatment standards. Turning Point Therapeutics Inc. specializes in precision medicines for cancer and other conditions, including tyrosine kinase inhibitors.
View the full tyrosine kinase inhibitors market report:
https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report
Innovative Trends Reshaping the Tyrosine Kinase Inhibitors Industry
Product innovation stands out as a critical trend within the tyrosine kinase inhibitors market. Leading companies are embracing cutting-edge technologies to maintain their competitive edge. For example, in February 2023, Swedish pharmaceutical company Xspray Pharma AB partnered with US-based life sciences service provider EVERSANA to support the launch and commercialization of Dasynoc in the U.S. Dasynoc is a novel therapy designed to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), addressing a $3.5 billion market for TKIs in the United States.
Clinical Insights Highlighting Treatment Advances
Dasynoc represents a significant advancement for CML patients. Retrospective data presented at the ASH 2022 meeting showed a 5-year overall survival rate of 79% for patients treated with both a tyrosine kinase inhibitor (TKI) and proton pump inhibitor (PPI) such as omeprazole, compared to a 94% survival rate for those on TKI therapy alone. This data underscores the importance of therapeutic innovation and combination strategies in improving patient outcomes.
Market Segmentation Overview of the Tyrosine Kinase Inhibitors Industry
This report segments the tyrosine kinase inhibitors market into key categories for detailed analysis:
1) By Type:
- BCR-ABL Tyrosine Kinase Inhibitor
- Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
- Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
- Other Types
2) By Distribution Channel:
- Hospital Pharmacy
- Independent Pharmacies
- Online Pharmacies
3) By Application:
- Chronic Myeloid Leukemia (CML)
- Lung Cancer
- Breast Cancer
- Renal Cell Cancer
- Other Applications
Detailed Subcategories Within the Market
Further breakdowns include specific drugs under each type:
- BCR-ABL TKIs: Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib
- EGFR TKIs: Gefitinib, Erlotinib, Afatinib, Osimertinib, Dacomitinib
- VEGFR TKIs: Sorafenib, Sunitinib, Pazopanib, Axitinib, Regorafenib
- Other Types: Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors, RET Tyrosine Kinase Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, and other emerging TKIs
This comprehensive segmentation helps clarify the landscape of the tyrosine kinase inhibitors industry and supports targeted strategies for future growth.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Analysis of Key Market Segments Driving the Tyrosine Kinase Inhibitors Market here
News-ID: 4318720 • Views: …
More Releases from The Business Research Company
Emerging Growth Patterns Driving the Expansion of the Skin Booster Market
The skin booster market is drawing considerable attention as it gears up for substantial growth over the next several years. Driven by shifts in consumer preferences and technological advancements, this sector is poised to expand significantly. Let's explore the current market size, leading players, emerging trends, and key segments shaping the future of skin boosters.
Projected Growth Trajectory of the Skin Booster Market
The skin booster market is anticipated to…
Overview of the Prescription Dermatological Drugs Market: Market Structure, Emer …
The prescription dermatological drugs sector is poised for substantial expansion in the coming years, reflecting growing demand driven by various healthcare and technological advancements. This overview explores the market's projected value, influential factors propelling growth, leading companies, emerging trends, and the crucial segments shaping the industry landscape.
Projected Market Size and Growth Trajectory in the Prescription Dermatological Drugs Market
The prescription dermatological drugs market is anticipated to grow significantly, reaching…
Emerging Sub-Segments Transforming the Urinary pH Modifier Market Landscape
The urinary pH modifier market is positioned for notable expansion in the coming years, driven by a range of health-related and technological factors. As healthcare continues to evolve with new demands and innovations, this market is set to respond with growing opportunities and advancements. Let's explore the market's size, key players, current trends, and important segments shaping its future.
Urinary pH Modifier Market Size and Growth Outlook
The valuation of…
Market Trend Analysis: The Impact of Emerging Developments on the Small Molecule …
The small molecule active pharmaceutical ingredient (API) market is on track for substantial growth over the coming years, driven by advancements in precision medicine and innovative technologies. With evolving pharmaceutical needs and strategic business moves, this market is set to expand considerably by 2029. Below, we explore the market's size, key players, emerging trends, and segment details to provide a comprehensive understanding of its trajectory.
Projected Market Size and Growth Outlook…
More Releases for Inhibitor
Advances in KRAS Inhibitor Development
The development of KRAS inhibitors has been a significant advancement in the field of oncology, offering new hope for patients with cancers driven by KRAS mutations. KRAS, a key gene involved in cell signaling, is frequently mutated in various cancers, including lung, colorectal, and pancreatic cancers. These mutations lead to uncontrolled cell growth and division, making KRAS a critical target for cancer therapy.
Download Report:
https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size
Historically, KRAS was considered an undruggable target…
Breakthroughs in KRAS Inhibitor Research
KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable."
Download…
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview
The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030.
Understanding Checkpoint Inhibitor Refractory Cancer
Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of…
Fibroblast Growth Factor Receptor Inhibitor Market - Maximizing Therapeutic Pote …
Newark, New Castle, USA: The "Fibroblast Growth Factor Receptor Inhibitor Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Fibroblast Growth Factor Receptor Inhibitor Market: https://www.growthplusreports.com/report/fibroblast-growth-factor-receptor-inhibitor-market/8933
This latest report…
Global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) Market Forecast 2023- …
The global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) market research report helps target customers understand the important driving factors and future opportunities of the industry. The report includes the dynamics of the macro environment such as the latest situation of the war between Russia and Ukraine, the update of monetary policy, and the impact of inflation on the market. Apart from this, the report studies key market developments such as…
Avionic and electronic component corrosion inhibitor
Super CORR A was originally developed for the U.S. Air Force to comply with Mil-DTL-87177B (formerly Mil-L-87177A) specifications. A water displacing lubricant and corrosion protection compound that prevents avionic as well as electrical and electronic components from systems failures caused by corrosion. It is now the industry standard for electrical corrosion protection, for in service maintenance by both military and commercial aircraft major repair and overhaul (MRO) facilities worldwide.
Super CORR…
